This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Commentary

Metabolic Effects of Treatment With Atypical Antipsychotics

John M. Kane, MD; Eugene J. Barrett, MD, PhD; Daniel E. Casey, MD; Christoph U. Correll, MD; Alan J. Gelenberg, MD; Samuel Klein, MD; and John W. Newcomer, MD

Published: November 1, 2004

Article Abstract

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

The metabolic effects of treatment with antipsychotic medications have been under considerable debate. The main purpose of this discussion is to allow readers to get a sense of the information that is available regarding metabolic effects and the studies that are underway to expand this information (Appendix 1). The knowledge base about metabolic effects is evolving, so some of the conclusions drawn in this discussion may be tentative. For a list of antipsychotic medications affected by the FDA’s recent request for a labeling change, see Table 1.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 65

Quick Links: Metabolic Disorder , Side Effects-Medication

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...